P/E ratio for Prometheus Biosciences (RXDX)
P/E ratio as of April 2024 (TTM): -56.8
According to Prometheus Biosciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -56.7955. At the end of 2022 the company had a P/E ratio of -31.6.
P/E ratio history for Prometheus Biosciences from 2021 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -31.6 | 190.19% |
| 2021 | -10.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Epizyme EPZM | N/A | N/A | 🇺🇸 USA |
 Akebia Therapeutics AKBA | -2.17 | -96.18% | 🇺🇸 USA |
 Agenus
AGEN | -5.85 | -89.71% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.